Prothena logo

ProthenaNASDAQ: PRTA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Ireland

IPO:

18 December 2012

Next earnings report:

14 February 2025

Last dividends:

N/A

Next dividends:

N/A
$940.08 M
-77%vs. 3y high
73%vs. sector
-vs. 3y high
-vs. sector
-79%vs. 3y high
51%vs. sector
-99%vs. 3y high
56%vs. sector

Price

after hours | Fri, 01 Nov 2024 21:34:32 GMT
$17.48+$0.15(+0.87%)

Dividend

No data over the past 3 years
$132.01 M$1.23 M
$132.01 M$66.89 M

Analysts recommendations

Institutional Ownership

PRTA Latest News

Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com29 October 2024 Sentiment: POSITIVE

Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?
zacks.com29 October 2024 Sentiment: NEUTRAL

Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Prothena Announces Leadership Team Updates
businesswire.com27 September 2024 Sentiment: POSITIVE

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that Chad Swanson, Ph.D., has been appointed Chief Development Officer.

What Makes Prothena (PRTA) a New Buy Stock
zacks.com19 August 2024 Sentiment: POSITIVE

Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
zacks.com09 August 2024 Sentiment: POSITIVE

Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.

Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?
zacks.com24 June 2024 Sentiment: POSITIVE

Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?
zacks.com07 June 2024 Sentiment: NEUTRAL

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
zacks.com29 May 2024 Sentiment: POSITIVE

Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.

Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline
Zacks Investment Research25 April 2024 Sentiment: NEGATIVE

Prothena (PRTA) lacks the necessary elements for a potential earnings beat in its upcoming report. Be ready with the important expectations.

Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense
Zacks Investment Research16 February 2024 Sentiment: NEGATIVE

Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.

  • 1(current)

What type of business is Prothena?

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

What sector is Prothena in?

Prothena is in the Healthcare sector

What industry is Prothena in?

Prothena is in the Biotechnology industry

What country is Prothena from?

Prothena is headquartered in Ireland

When did Prothena go public?

Prothena initial public offering (IPO) was on 18 December 2012

What is Prothena website?

https://www.prothena.com

Is Prothena in the S&P 500?

No, Prothena is not included in the S&P 500 index

Is Prothena in the NASDAQ 100?

No, Prothena is not included in the NASDAQ 100 index

Is Prothena in the Dow Jones?

No, Prothena is not included in the Dow Jones index

When was Prothena the previous earnings report?

No data

When does Prothena earnings report?

The next expected earnings date for Prothena is 14 February 2025